HR+breast cancers, including Luminal A (HR+/Human Epidermal Growth Factors Receptor 2 (HER2)−) and Luminal B (HR+/HER2+) tumor subtypes, have receptors for either estrogen or progesterone, or both, and therefore, are more likely to respond to hormone therapy than other subtypes [2]. This evidence concerns the gene ERBB2 and breast carcinoma.